Table 4 Summary of statistical analyses in all samples
From: A pharmacogenetic intervention for the improvement of the safety profile of antipsychotic treatments
Clinical variable | All patients (N = 290) | Clozapine treated patients (N = 131) | Patients treated with CYP2D6 substrates (N = 61) | |||
|---|---|---|---|---|---|---|
PharmG+ (N = 123) | PharmG− (N = 167) | PharmG+ (N = 43) | PharmG− (N = 88) | PharmG+ (N = 26) | PharmG− (N = 35) | |
Difference in PANSS average | 26.81 + 1.3 | 26.60 + 1 | 29.36 + 2.3 | 26.0 + 1.4 | 24.33 + 3.0 | 26.47 + 2.0 |
Model χ2 (p value) | 6.72 (0.24) | 8.54 (0.08) | 2.90 (0.72) | |||
PI Wald (p value) | 0.04 (0.84) | 1.32 (0.25) | 0.34 (0.56) | |||
Difference in UKU scores | 3.62 ± 0.66 | 3 ± 0.56 | 3.81 ± 1.10 | 2.67 ± 1.03 | 4.04 ± 1.34 | 2.69 ± 1.11 |
Model χ2 (p value) | 10.19 (0.07) | 5.67 (0.23) | 2.79 (0.73) | |||
PI Wald (p value) | 0.40 (0.53) | 0.002 (0.97) | 0.38 (0.54) | |||
Difference in psychic SE | 2.02 ± 0.36 | 1.26 ± 0.30 | 1.84 ± 0.63 | 1.38 ± 0.52 | 1.60 ± 0.72 | 0.53 ± 0.53 |
Model χ2 (p value) | 10.38 (0.07) | 3.26 (0.52) | 7.71 (0.17) | |||
PI Wald (p value) | 1.53 (0.22) | 0.03 (0.86) | 0.64 (0.42) | |||
Difference in neurological SE | 0.87 ± 0.20 | 0.94 ± 0.25 | 0.98 ± 0.32 | 0.54 ± 0.51 | 1.04 ± 0.48 | 1.25 ± 0.56 |
Model χ2 (p value) | 12.49 (0.03) | 12.65 (0.01) | 2.01 (0.85) | |||
PI Wald (p value) | <0.01 (0.99) | 0.01 (0.91) | 0.08 (0.78) | |||
Difference autonomic SE | 0.32 ± 0.26 | 0.17 ± 0.12 | 0.16 ± 0.51 | 0.37 ± 0.37 | 0.71 ± 0.45 | 0.28 ± 0.16 |
Model χ2 (p value) | 4.09 (0.54) | 4.42 (0.35) | 10.03 (0.07) | |||
PI Wald (p value) | 0.35 (0.56) | 0.47 (0.49) | 0.93 (0.33) | |||
Difference in other side effects | 0.54 ± 0.24 | 0.52 ± 0.23 | 0.93 ± 0.30 | 0.38 ± 0.41 | 0.56 ± 0.30 | 0.44 ± 0.29 |
Model χ2 (p value) | 9.67 (0.09) | 2.53 (0.64) | 2.45 (0.78) | |||
PI Wald (p value) | 0.003 (0.95) | 1.32 (0.25) | 0.07 (0.79) | |||
